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into the process as appropriate. RESULTS: Two main linguistic and conceptual issues 
emerged during the translation process. Firstly, when an original item used more than
one adjective to cover a single concept, some languages only had one term to express 
this. Secondly, there was the challenge of using culturally appropriate expressions for
taboo concepts such as suicide and self-harm, to ensure homogenous response across
all languages. CONCLUSIONS: The language versions of the GAD-7 and PHQ-9 were 
established according to a rigorous standardized methodology to facilitate interna-
tional comparison and pooling of data. The linguistic validation process aims to ensure
conceptual equivalence across different language versions on the basis of a pre-deﬁ ned 
concept list explaining what the original instrument should measure. The process as 
a whole supports the advantage of integrating international feedback on concepts and 
wording during the development of questionnaires.
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EVALUATION OF GLP-1 PRODUCT ATTRIBUTES IN TREATING PEOPLE
WITH TYPE-2 DIABETES IN US: COMPARING TIME-TRADEOFF AND
WILLINGNESS-TO-PAY METHODOLOGIES
Zanutto E1, Conner C2, Polster M3, McDonald SS1, Hammer M4
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OBJECTIVES: To assess patient utilities for cost utility analyses in health economics 
two different ways of revealing preferences have been compared. Time trade-off (TTO) 
and willingness-to-pay (WTP) surveys have been completed comparing patients’ pref-
erence in product propositions. TTO yields estimates of the amount of time that
patients would be willing forego to achieve preferred products attributes, and WTP 
yields estimates of the amount of money that patients are willing to pay for products 
attributes. Despite their widespread use, results of the two methodologies have not, 
to our knowledge, been compared directly in diabetes. METHODS: The two methods
were used to evaluate the reactions of people with type-2 diabetes to two GLP-1
injectable diabetes medications that varied on four attributes: efﬁ cacy in controlling 
blood glucose (measured by HbA1c), dosing frequency (twice-daily vs. once-daily), 
incidence of hypoglycemia, and incidence of nausea. To maximize statistical power
and allow comparisons across patient groups, a large internet-based survey (more than 
500 respondents) was conducted in U.S. with four categories of self-identiﬁ ed patients 
who were sampled based on their medication history, and randomly assigned to either 
the TTO or WTP. RESULTS: Results suggest that the WTP methodology yields greater 
face validity and sensitivity than TTO (100% of respondents prefer the superior proﬁ le 
in WTP vs. 96% in TTO). Data from conjoint analysis designed to establish the 
importance of each of the four product attributes in the decision-making process used 
by patients reveal similar patterns of results for the two methodologies. CONCLU-
SIONS: Regardless of whether patients were in the group assigned to TTO or WTP,
patients perceive efﬁ cacy (HbA1c control) to be the most important product attribute,
followed by incidence of nausea. Patients evaluated the incidence of hypoglycemia and 
dosing schedule as less important relative to the HbA1c control and nausea in the 
decision-making process.
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QUALITY-ADJUSTED LIFE YEARS SAVED BY PREVENTION OF HEAD 
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OBJECTIVES: To evaluate the potential long-term health impact of helmet law, we 
calculated the loss of quality-adjusted life year (QALY) under different proportions of 
helmet wearing among the motorcyclists. METHODS: The quality-adjusted life expec-
tancies for helmeted and non-helmeted motorcyclists were estimated by adjusting the 
survival function based upon the Head Injury Registry with quality of life measures 
assessed under the EQ-5D questionnaire. We took Hualien County, where a lower rate 
of helmet wearing (77%) was reported, as an example to calculate the expected
numbers of prevented head-injured cases by multiplying the population at risk with 
the incidence rate of head injury for helmeted and non-helmeted motorcyclists. As dif-
ferent proportions of helmet-wearing and different proportions of full face helmet in 
motorcyclists were assumed, the expected numbers of prevented cases were calculated, 
which were multiplied with the loss of QALE of an average case to predict the potential 
beneﬁ t of helmet use. RESULTS: Under the current proportion of helmet wearing, the
annual loss associated with head injured was 4346.9 QALYs in Hualien County. If the
proportion of helmet wearing could be increased to 100%, the health beneﬁ t saved 
was estimated 1434.3 QALYs. If 80% of them used full face helmet, the total gain was 
increased to 2500 QALYs. CONCLUSIONS: The health beneﬁ t of helmet protection 
for head injury can be determined under units of quality-adjusted life year (QALY) and 
directly applied in future cost-effective analyses for public health policy.
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MEANINGFUL VERSUS USEABLE RESPONSES TO PREFERENCE
SURVEYS: INSIGHTS INTO IMPROVING THE VALIDITY OF
 HEALTH UTILITY SCORES
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OBJECTIVES: To identify the types of and reasons for unusable preference survey
responses with the goal of informing improvements in health utility assessment meth-
odology. METHODS: We deﬁ ne typologies that represent unusable responses from
health utility surveys; present evidence from the literature on the frequency of such
responses; present empiric data on the rationale for such types of responses; and 
discuss methods for handing data that contain such responses, and implications for 
interpreting analytic results based on health utility data. RESULTS: Potentially unus-
able health utility survey responses include (1) illogical, (2) inconsistent, (3) invariant, 
and (4) “protest” responses, plus (5) refusals. These responses may represent simple 
mistakes or misunderstandings of the survey task, which introduce noise into results,
or they may be intentional responses to the parameters of the survey task that may 
confound respondents’ other values with the value of the health state being assessed. 
Unusable responses can be avoided through anticipation and careful design of survey 
instruments, particularly for speciﬁ c populations and health states, including cognitive
testing prior to ﬁ elding. Unusable responses can also be omitted from analyses or
analyzed separately. CONCLUSIONS: Unusable health utility survey responses chal-
lenge the validity of utility estimates and all analyses that incorporate these values, so
it is critical to minimize these responses. Mechanisms to correct errors are useful, but
may not address true preferences that are in response to elements of the measurement 
task and hence will not be corrected. Correction mechanisms may include tailoring
the task to particular situations when bias is anticipated, such as parent valuations of 
children’s states or individuals who express religious beliefs. Recognition of the preva-
lence of unusable data in health utility data sets and identifying methods for handling 
these errors is essential to understand the accuracy and precision of results and analy-
ses that depend thereon.
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AN ASSESSMENT OF THE EVIDENCE TO SUPPORT THE USE OF
LINGUISTIC VALIDATION INTERVIEWS AS AN INTEGRAL PART OF
THE TRANSLATION OF PROS FOR USE IN MULTI-NATIONAL TRIALS
Gordon-Stables R, Houchin C, Wild D
Oxford Outcomes Ltd, Oxford, UK
Linguistic validation interviews are considered a vital step in the generally accepted
methodology for the translation of PRO measures. The translated PRO measure is 
administered to 5 or more native-speakers of the target language who also have a 
diagnosis of the condition of interest. OBJECTIVES: The objective of this study was 
to determine whether there is any evidence to suggest that the changes made are sig-
niﬁ cant enough to make the step worthwhile. METHODS: Examples of linguistic
validation changes were gathered from completed PRO translation projects. For one 
scale for which 26 translations were developed, changes made at the linguistic valida-
tion stage were examined quantitatively and qualitatively in order to determine the
number of changes made and the nature of these changes. The number of changes 
made per language as a result of the linguistic validation step ranged from 0 to 11,
with a mean of 1.4 changes. The changes made can be categorised as follows: Items 
where participants reported they did not understand. Items where participants
reported that they understood, but probing made it clear that confusion had arisen. 
Items where participants picked up on vocabulary that was not what they would
usually use, and items where participants spotted spelling and grammatical errors.
RESULTS: Whilst in purely numerical terms, the contribution of linguistic validation
to the translation process may seem small; in terms of the importance of those changes 
and in the conﬁ rmation of accuracy of the translated concept, its contribution is great. 
Whilst the translation may appear to be “correct” in other stages, only linguistic vali-
dation interviews show if the target population understands the translation as 
intended. CONCLUSIONS: The goal of translation of a PRO instrument is to achieve 
conceptual equivalence, and linguistic validation is arguably the most important step 
in assuring this.
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Eremenco S1, Coyne KS1, Duran B2, Leidy NK1
1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corporation, 
Lexington, MA, USA
BACKGROUND: As electronic patient-reported outcome (ePRO) use expands, ques-
tions have arisen regarding the effect of presentation form and style on patient inter-
pretation and whether there is an optimal format to ensure clarity, ease of use, and
data quality. OBJECTIVES: To develop and validate a standardized ePRO interface
of common PRO question formats for use on desktop and tablet PCs to streamline
ePRO study implementation. METHODS: A web-based application was developed 
for desktop and tablet platforms with 52 demographic and clinical questions repre-
senting Likert-type, dichotomous, VAS and numeric rating scales. Adults from the 
general population were recruited through newspaper advertisements to participate in 
questionnaire completion and a cognitive debrieﬁ ng interview. Participants answered 
questions on either desktop or tablet PC and then reviewed the alternate format during 
the interview. Alternative question formats were reviewed to obtain further respondent 
insight and recommendations. RESULTS: Participants: N  47: mean age 54 years (23 
to 79), 51% female; 49% reported a chronic condition. 13% igh school education. 
Average completion time: desktop (n  22)  11 minutes; tablet PC (n  25)  13 
minutes, with all participants ﬁ nding their completion time acceptable. A total of 53% 
preferred desktop to tablet. Respondents found question formats easy to answer, 
except items requiring date and time entry (resolved through minor instruction revi-
sions) and the VAS. The VAS was presented three ways: anchors at 0 and 100, hash-
marks every ten digits, and hashmarks only with a display of the number selected.
77% preferred hashmarks; 83% liked the number displayed. No participants changed
their answer after the number appeared. CONCLUSIONS: Respondents provided
useful information on their perception and preferences for question format presented 
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on desktop and tablet PC platforms. Results of the interviews informed the develop-
ment and ﬁ nal testing of a standardized interface that can be used across studies to
facilitate rapid deployment of ePRO studies.
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TRANSLATION OF THE PATIENT-REPORTED OUTCOMES
MEASUREMENT INFORMATION SYSTEM INTO SPANISH
Arnold BJ, Correia H, Cella D
NorthShore University HealthSystem, Evanston, IL, USA
The Patient-Reported Outcomes Measurement Information System (PROMIS) pro-
vides accurate and efﬁ cient measurement of patient-reported outcomes. Developed in 
English using qualitative methods, PROMIS seeks to measure symptoms, such as pain
and fatigue, and aspects of health-related quality of life across a wide variety of chronic 
diseases and conditions. OBJECTIVES: In order to enable participation of the rapidly 
growing Spanish-speaking population of the USA it was necessary to translate 
PROMIS banks from English into Spanish using methods that would ensure linguistic 
equivalence and cultural appropriateness. METHODS: Five hundred and twenty-two
items were translated into Spanish using the FACIT Multilingual Translation Meth-
odology which consists of the following twelve steps: (1) translatability review of 
existing English items, (2) creation of item deﬁ nitions, (3) two simultaneous forward 
translations,(4) reconciliation of forward translations, (5) back translation of recon-
ciliation, (6) expert review of back translation and previous steps, (7) preliminary 
ﬁ nalization for pilot-testing, (8) harmonization, (9) quality assurance, (10) formatting,
(11) cognitive testing with native speakers of Spanish and (12) analysis and ﬁ nalization 
of translations based on qualitative data collected during pilot-testing. Recognizing 
the need to address diversity within the Spanish-speaking population of the USA, lin-
guists from various Spanish-speaking regions across the globe were recruited to
achieve a universal Spanish translation. RESULTS: Some of the linguistic challenges 
encountered during the translation process as well as the language solutions for resolv-
ing difﬁ culties associated with the cultural and linguistic heterogeneity of the Spanish-
speaking population residing in the USA will be highlighted in this presentation. 
CONCLUSIONS: Future research includes further validation of the Spanish transla-
tions using psychometric testing of the equivalence of banks in English and Spanish,
including assessment of differential item functioning across different cultural groups. 
The translation of additional items into Spanish and into other languages is also 
explored in this presentation.
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ELECTRONIC PATIENT REPORTED OUTCOMES: FOLLOWING
FDA GUIDANCE FROM A VENDOR PERSPECTIVE
Ross J, Shea E
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OBJECTIVES: To provide an overview of considerations sponsors/vendors need to
address in order to meet FDA expectations during the planning and implementation 
phases when using Electronic Patient-Reported Outcomes (ePROs) in clinical trials, 
to understand important considerations required in ePRO-use when planning and 
implementing clinical trials, identify essential considerations from a vendor’s perspec-
tive, and following FDA guidance as a vendor or when using a vendor. METHODS:
Sponsors often utilize vendors for the planning and implementation of their trials.
When vendors are involved in these phases with ePRO, it is not only the sponsor’s
responsibility, but also the vendor’s to address considerations to ensure FDA expecta-
tions are met. However, meeting these expectations can be challenging across the
pharmaceutical industry. To assist industry, the FDA released a Draft Guidance to
communicate their perspective on how they evaluate ePRO-use for efﬁ cacy endpoints
in clinical trials and for support claims made in approved product labeling. RESULTS:
Often, sponsors/vendors are unsure how to follow the guidance and are unaware of 
important considerations necessary when incorporating them in clinical trials. These
considerations can include: standardizing data collection with electronic tools, han-
dling missing values, validation, reliability, and responsiveness to clinically signiﬁ cant
differences. EPRO-use in clinical trials requires careful planning and execution. When
these considerations are not satisﬁ ed, the trials can face serious consequences by the
FDA throughout the product development and approval processes. CONCLUSIONS:
This session intends to provide an overview of how FDA ePRO-use expectations 
should be met from the perspective of a vendor during the planning and implementa-
tion phases of clinical trials. Key considerations will be discussed. Fictitious examples 
of what could go wrong will be presented. A summary of recommendations will be
provided on how to follow the FDA guidance and avoid making critical errors when 
employing ePROs in clinical trials.
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PSYCHOMETRIC PROPERTIES OF FOUR KISWAHILI TRANSLATED
DISEASE SPECIFIC PATIENT REPORTED OUTCOME MEASURES
Kangethe AW, Franic DM
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OBJECTIVES: Kiswahili (Swahili) is the operative language of 100 million East Afri-
cans. Most patient reported outcome (PRO) measures are developed in the Anglo-
American literature; however, no disease speciﬁ c studies have been published on their
translation into Kiswahili. This project assessed the 1) psychometric properties, and 2) 
cross cultural adaptation of disease speciﬁ c (PRO) measures translated from English .to 
Kiswahili. METHODS: A comprehensive literature and web search identiﬁ ed four
Kiswahili translated PRO measures for study inclusion. PRO measures were included 
for evaluation: if there was at least one peer reviewed English publication providing
psychometric data, and instrument availability. Psychometric instrument evaluation
criteria were based on: conceptual model, practicality (5–15 minutes), depth, reliability
(internal consistency, test-retest: greater than or equal to .7), validity (convergent and 
divergent), and responsiveness (Lohr, 2002). Assessment of the procedures used to
evaluate conceptual and linguistic equivalence was based on recommendations by 
ISPOR Taskforce for Translation and Cultural Adaptation (Wild et al, 2005). RESULTS:
Of the four instruments evaluated: Oral Impacts on Daily Performance (OIDP), Patient
Health Questionnaire – 9 (PHQ-9), World Health Organization Prevention of Blind-
ness and Deafness Visual Functioning-20 (WHO/PBD VF20) and Hopkins Symptom 
Check List-25 (HSCL-25), none met all study criteria for psychometric properties or 
linguistic adaptation procedures. Conceptual model, practicality and internal consis-
tency were met for all scales. In cases where criteria were not met it was predominantly 
due to missing data, e.g, divergent validity was unavailable for the PROs assessed.
CONCLUSIONS: Although attempts to provide good practice guidelines on transla-
tion of PRO instruments have been made, there is need to reach a consensus on these 
guidelines. Researchers involved in the cross cultural adaptation of PRO instruments 
are encouraged to be transparent to enable the complete evaluation and subsequent 
adoption of the translated scale into clinical practice or clinical trials.
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USE OF CONJOINT ANALYSIS IN HEALTH OUTCOMES
RESEARCH: AN EXAMINATION OF THE LITERATURE
Szeinbach SL, Beyer AP, Qureshi ZP, Uhas AA, Visaria J, Seoane-Vazquez E
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Patient-reported outcomes (PRO) are key endpoint measures to examine and assess 
preferences for health improvements. Conjoint analysis (CA), traditionally used in
marketing studies to examine tradeoffs among attributes, has gained popularity in
health care and PRO studies. However, the use of CA and the type of CA studies
performed in health care has not been fully characterized. In this study, we character-
ized the current trends for CA, classiﬁ ed CA studies by area of focus, examined study
complexity, and provided recommendations for future research. Literature reviews 
were conducted using a multi-database search from 2000 to 2008. Review articles,
methodological, and non-health related CA studies were excluded. Preference studies
were coupled with key words such as: conjoint, health, disease, evaluation, discrete 
choice and outcome(s). Five years were selected for detailed content analysis and re-
checked for accuracy. For the ﬁ ve years examined, there was an upward trend for the 
number of health-related CA studies (2000  22; 2002  39; 2004  38; 2006  56; 
2008  70). However, results from Chi-square analysis revealed no signiﬁ cant differ-
ences among years for the general area of focus for CA studies performed. The largest 
proportion of CA studies consisted of attribute importance, risk, and pharmacoeco-
nomics studies where utility estimates were used to assess willingness-to-pay, quality 
of life, or quality-adjusted life years. Other applications included disease screening, 
value of services, satisfaction, treatment evaluation and service delivery. The use of 
CA to assess PROs in health research has expanded. Recent and more innovative
applications have extended to adherence, disease screening, technology, and value. 
More research is needed to evaluate the usefulness of CA for large database studies
and for economic analyses in health technology assessment.
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THE POWER OF ASSUMPTIONS
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OBJECTIVES: Studies powered using a dichotomous endpoint, are often too small to 
ﬁ nd signiﬁ cant differences in quality of life (QoL) or costs. Including the likelihood 
that events in both arms are similar, using either frequentist assumptions or Bayesian 
priors, may increase the power. METHODS: A study of patients with late pain is 
imagined. With therapy, 92% is expected to be pain-free, without 85%. With 2 r 250 
patients, the dichotomous power (pain: yes/no) is 80%. Using the EQ-5D utility score 
it is 40% (with the EQ-5D-pain-dimension at 3 with pain and at 0 without pain and 
the other EQ-5D-dimensions at random population levels). Trials are simulated and
T-tests are calculated based on: 1. QoL of patients with pain is identical in both arms;
2. QoL of patients without pain is identical in both arms; 3. 1  2. 95% credibility 
intervals are calculated using normal priors concerning the difference in QOL (per 
arm) with and without pain. Expectations and precisions are varied as well as base
line probabilities. RESULTS: Making both assumptions, using T-tests, increases the 
power from 40% to 80%. Assumption 1 does so by 2%, assumption 2 by 79%. Both
assumptions contribute equally when the expected pain-free levels are approximately
55% versus 44% instead of 95% versus 82%. The Bayesian model coincides with the
frequentist approach when the precision in the priors concerning the differences in
QoL are set to the extremes (zero or inﬁ nity). Between the extremes the Bayesian
approach offers the ﬂ exibility to compromise. The power increase between the 
extremes can be characterized by a cumulative normal distributions on the log of the 
squared root of the precisions. CONCLUSIONS: Predeﬁ ning logical assumptions in
a QoL analysis may increase the power of a study. The larger the group of patients 
the assumption is applied to, the bigger the power increase.
